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compare trajectories of amphetamine type
stimulant consumption in different user
groups: a cross-sectional study
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Abstract
Background: Amphetamine-type stimulants (ATS) are the second most commonly used illicit drugs in Europe and
globally. However, there is limited understanding of what shapes patterns of ATS use over the life course. The ATTU
NE project “Understanding Pathways to Stimulant Use: a mixed methods examination of the individual, social and
cultural factors shaping illicit stimulant use across Europe” aims to fill this gap. Here we report initial findings from
the life course chart exercise conducted as part of qualitative interviews with ATS users and nonusers.
Methods: Two hundred seventy-nine in-depth qualitative interviews were conducted with five ATS user groups
(current and former dependent users;current and former frequent users;non-frequent users) and one group of
exposed non-ATS users in five European countries (Germany, UK, Poland, Netherlands and Czech Republic). As part
of the interviews, we used life course charts to capture key life events and substance use histories. Life events were
categorised as either positive, neutral or negative, and associated data were analysed systematically to identify
differences between user groups. We applied statistical analysis of variance (ANOVA) and analysis of covariance
(ANCOVA) to test for group differences.
Results: Out of 3547 life events documented, 1523 life events were categorised as neutral, 1005 life events as
positive and 1019 life events as negative. Current and formerly dependent ATS users showed more negative life
events for the entire life course after age adjustment. Although some group differences could be attributed to the
individuals’ life course prior to first ATS use, most negative life events were associated with periods of ATS usage. A
detailed analysis of the specific life domains reveals that dominantly, the social environment was affected by
negative life events.
Conclusions: For non-dependent, frequent and non-frequent ATS users, negative life events from the period of
ATS use do not become obvious in our analysed data. Besides preventing a pathway into ATS dependency, the aim
of an intervention should be to reduce the harm by for example drug testing which offers also the opportunity for
interventions to prevent developing a substance use dependency.
For the group of dependent ATS users, our study suggests holistic, tailored interventions and specialist treatment
services are needed, as a single, simple intervention is unlikely to cover all the life domains affected.
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Background
Amphetamine-type stimulants (ATS) refers to a range
of drugs including amphetamine, methamphetamine,
3,4-methylendioxy-methylamphetamin (MDMA and
ecstasy), fenethylline, ephedrine and prescribed drugs
containing methylphenidate (e.g. “Ritalin®”). According
to the United Nations Office on Drugs and Crime
(UNODC) [1], ATS use is rising rapidly, with seizures
of ATS having doubled in the 5 years prior to 2015
(191 tons in 2015). The UNODC estimated that there
were 37 million users of amphetamines and 22 million
users of ecstasy worldwide in 2015 [1], making ATS
the second most commonly used illicit drugs after
cannabis [1].
In Europe, as in other parts of the world, a number of
different indicators reveal widespread use of amphet-
amines and ecstasy [2]. The EU drugs agency (European
Monitoring Centre for Drugs and Drug Addiction—
EMCDDA) in association with the Sewage Analysis
CORe group Europe (SCORE), analysed urinary
biomarkers in the wastewater of 56 European cities to
explore drug-taking habits for amphetamine, metham-
phetamine and MDMA [3]. The highest level of amphet-
amine detected in wastewater was found in cities in the
north and east of Europe, while methamphetamine levels
were highest in cities in the Czech Republic, Slovakia,
Eastern Germany and Finland. Belgium, Germany and
the Netherlands also reported the highest levels of
MDMA use. According to the EMCDDA, among
Europeans aged 15–34, the 12-month prevalence of
amphetamine use was highest in the Netherlands, at
3.6% [4]. Amphetamine use prevalence was also high in
Finland (2.4%), Germany (1.9%) and Czech Republic
(1.7%). For the same age group, the 12-month preva-
lence for MDMA was significantly higher. Again, the
highest MDMA 12-month prevalence was found in the
Netherlands (7.4%), with high rates of 12-month use also
found in Ireland (4.4%), Czech Republic (4.1%), Bulgaria
(3.1%) and the UK (2.6%).
A number of previous studies have focussed on in-
creasing our understanding of which factors influence
the initiation of amphetamine use [5, 6], and in particu-
lar, the transition into methamphetamine [7–11] or
ecstasy [12, 13] consumption. Research to date suggests
that a range of individual, social and environmental fac-
tors affect ATS initiation. These include personality
traits, with some evidence to suggest that hedonism,
shaped by a curiosity about the ATS effects, sensation
seeking and propensity for experimentation, can
contribute to initiation of ATS use [5, 11–13]. Further-
more, self-management or coping with mental health
problems and trauma have also been identified as a
common reason for initiating ATS, especially for meth-
amphetamine users [5–8, 10, 12]. Carbone-Lopez et al’s
qualitative study of the experiences of female meth-
amphetamine users living in a Missouri prison found
that the majority had experienced critical adverse
events in childhood [9]. Family dysfunction (parental
mental health problems, domestic violence) and
experiences of physical or sexual violence often trig-
gered the transition into the use of methamphet-
amines for these women. Studies also suggest that
prior to ATS initiation, most users have tried other
substances, including alcohol, tobacco and marijuana,
at a relatively early age (12–14 years) [9, 11, 13].
Social factors also play a key part in influencing ATS
initiation, in particular, having friends and/or intimate
partners who are already using ATS [6, 7, 9, 10, 12]
and/or pressure from close peers [9]. Previous
research also highlights functional use of ATS, where
consumption is motivated by the desire to increase
energy levels to manage the pressures of work, family
or life in general [10].
However, whilst several studies have been published
exploring factors shaping initiation, there is less
available evidence about what affects the subsequent
development of ATS consumption over time [14]. A
recent review of qualitative literature exploring the in-
dividual, social and environmental influences on ATS
use concluded that a variety of interrelated factors
affected key turning points in drug use trajectories
[14]. Both the initiation and continued use of ATS
were associated with family, friends and social net-
works and were linked to individual and social
stressors, as well as ongoing health problems and crit-
ical life events. Specifically, three major factors have
been identified as motivating the continued use of
ATS: perceived functionality for stress management,
boosting sexual pleasure, clubbing, and reduced inse-
curity in social situations [9, 15–19]; critical life
events such as unemployment, death of a close
person, separation from close persons, domestic
violence [6, 10, 20]; and withdrawal effects [21–23].
Yet there remains a limited understanding of how
ATS use trajectories may vary between different
groups of users, the pathways into use and the circum-
stances which lead to more controlled or more
problematic consumption patterns.
The European study “Understanding Pathways to
Stimulant Use: a mixed methods examination of the
individual, social and cultural factors shaping illicit
stimulant use across Europe” (ATTUNE) seeks to
respond to this evidence gap by exploring and com-
paring the different substance use pathways of five
specific ATS user and one non-ATS user groups.
Research institutions from Germany, the United
Kingdom (UK), Poland, the Netherlands and the
Czech Republic formed a consortium to examine
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interactions between potential influencing factors and
the trajectories of the ATS use in all five countries.
The research study is the first of its kind as it applies
qualitative and quantitative methods to generate an
in-depth, contextualised understanding of ATS use
over the life course [24].
In this paper, we report on the analysis of life course
charts completed as part of semi-structured qualitative
interviews with ATS users and non-users across Europe.
The aim of this paper was to identify life events associ-
ated with the individuals’ substance use trajectory.
Methods
ATTUNE is a cross-sectional mixed-methods study
which seeks to explore the dynamics and trajectories
of different ATS use patterns in Europe. In addition
to systematic reviews of the existing qualitative and
quantitative literature on ATS use, ATTUNE com-
prises two key components. First are the in-depth
semi-structured interviews with ATS users and non-
users to explore experiences with ATS over the life
course and to identify key turning points in their
consumption patterns. Second is the structured
questionnaire administered by computer tablet to a
larger sample of users and non-users to validate and
generalise the qualitative interview findings.
The semi-structured interviews employed two topic
guides: one for ATS users and one for non-ATS users
who were exposed to ATS (defined as having been
present when family or friends took ATS but did not
consume themselves and have never taken ATS during
their entire life course). The topic guides covered aspects
of initiation, continuation and increase and decrease of
ATS consumption. As part of these interviews, life
course charts were used to help provide a chronological
structure for discussions about ATS use over time and
to capture more detailed data on participants’ living
environment, health conditions, social functioning, life
events and broader lifestyle. The life course charts were
used here with the very specific intention of providing a
more systematic means of recording valuable contextual
data. Here we report exclusively on findings from the
analysis of the life course data.
Ethical approval for data collection and use was
secured in five of the six participating countries, and
in the Netherlands, an ethical approval was not
required. All participants received an information
leaflet about the study, informed consent was then
obtained and anonymity and confidentiality protected.
The interviews were audio-recorded and transcribed
in full. Trained and experienced fieldworkers imple-
mented the interviews that lasted between 60 and 90
min. Participants also received a small incentive after
the interview, by way of thanks for their time.
Life course charts
Life course charts have been used previously in qualita-
tive research as a means of contextualising individual
semi-structured interviews [25]. In the substance use
field, life course charts are used to assess the intensity of
drug use at critical time points in a participants’ history
and to observe possible associations between critical life
events and changes in the drug use trajectory. One
particular study with substance using adolescents found
that life course charts enhanced the memory of the
respondents to recall their drug career and significant
life events in chronological order [26–28]. A review of
the use of calendar or timeline instruments demon-
strated that these types of instruments contributed to
improved data quality as they helped respondents relate
specific events and dates to different behaviours and
consequences [27].
Timeline instruments have the structure of a chart,
with rows referring to the person’s life in years and
columns representing different aspects of life (life
domains) and substance use, which can vary by study
[26, 27]. For this research, a life course chart was
developed which reflected the overarching study
objectives (see Fig. 1 in Appendix 1). This study used
the following defined periods in an individual partici-
pants’ life course: until the age of 13, age 14–16, age
17–19, age 20–25, age 26–30, age 31–39, age 40–49
and age 50+. The chart included two separate
sections, one referring to substance use and one
referring to life events. The section on substances
covered the use of different ATS, cannabis, cocaine,
opiates and alcohol. The drug use pattern was
recorded for each time period by asking users to
identify how frequently particular substances were
used out of the following five options: no use, use
less than monthly, monthly use, weekly use or
(almost) daily use. Where the frequency of use varied
significantly within one time period, the most
frequent use was entered into the life chart. The life
event section included 11 different domains, including
family history, education, friends, health and illness,
involvement with the criminal justice system, sub-
stance use treatment and leisure.
The life course chart was implemented as part of
the semi-structured, face-to-face interviews with ATS
users and non-users. Whilst the life course chart
provided interviewers with structured prompts to
motivate the interviewer to ask for details of specific
live events, the instrument itself was administered
iteratively to reflect the fact that certain life events
may not have been experienced by some respondents
or were not felt to be especially significant. For each
of the specific time periods and associated life
domains, only one significant life event could be
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recorded. Where two key life events were reported
for the same life domain and time period, the more
critical negative life event was noted.
Sampling criteria and recruitment
To be eligible for inclusion, the first consumption or
exposure to ATS needed to have been at least 5 years
before the interview took place. Further inclusion
criteria were that individuals should be: 18 years or
older, have no opioid dependency in their lifetime
(with five exceptions for the UK sample), resident in
one of the five countries and able to participate in
the interview. The inclusion criteria were reviewed
with each individual via a standardised screening
checklist and only eligible individuals were
interviewed.
To ensure variation in ATS pathways and trajector-
ies, we targeted five predefined groups of ATS users
and a further group of non-users. Eligible interview
participants were allocated to one of the study
groups, depending on their consumption pattern, their
ATS dependency level and current state of use (Table 1).
Dependency was measured with the Severity of
Dependence Scale (SDS), which is a five-item ques-
tionnaire that provides a score indicating the severity
of dependence on amphetamines [29]. An ATS
related SDS greater or equal four was approximated
as dependency. Former ATS users (defined as not
having used ATS in the last 12 months) were asked
to fill in the SDS for the phase when their ATS use
was the most intense in their life. Current ATS users
related the SDS to the last 12 months, and if this
result was negative, the SDS was administered again
to relate to the most intensive phase.
We aimed to purposively sample five participants
per study group in the Czech Republic and 10 partici-
pants per group in the other four countries. Partici-
pants were recruited into the study using a number
of recruitment strategies, including advertising the
study by flyer, poster and social media, via contacts
within drug and health services, and by interviewees
who shared the study link within their networks
(snowball sampling). The interviewees were asked
how they learnt about the study and more than half
of them (51%) were informed by friends or family
members. Almost a quarter of participants were
recruited by staff of drug treatment services (24%), a
smaller number responded to the flyer and posters
(16%) and the remaining interviewees heard about the
study through social media or from researchers.
In total, 279 eligible participants across five countries
participated in the interviews. However, the target
sample for each study group could not be realised in all
countries (Table 2). While in group 2 (FDU—formerly
ATS-dependent users) the recruitment target was
exceeded, group 4 (FFU—formerly frequent ATS users)
proved difficult to access, especially in Germany and
Poland.
The interviews were performed by national experi-
enced expert teams. All interviewers were familiarised
with the interview materials prior to data collection,
all guidance materials were utilised and translated
into the national languages where applicable. The
Czech partner engaged three well-experienced qualita-
tive researchers, two on post PhD employment; in
Germany, the team comprised of three post PhD and
two senior researchers; in the Netherlands, experts
comprised two persons with experiences in qualitative
interviewing, one with MSc and one PhD; in Poland,
the team was led by an assistant professor (15
interviews) supported by one experienced university
researcher, two experienced external interviewers and
two well-trained university co-workers. For the UK,
all interviewers were experienced in qualitative
interviewing (two post PhD and one MSc) and
completed the National Institute for Health Research
Good Clinical Practice training.
Characteristics of the participants
41.2% of the participants were female, and the mean
age of all participants was 31 years (Table 3). On
average, exposure and use of ATS first occurred
when participants were 18 years old. More than a
third of participants had, at some point, been in
Table 1 Operationalisation of the study groups
Group 1: currently
ATS dependent
(CDU)
Group 2: formerly ATS
dependent users (FDU)
Group 3: currently
frequent, non-dependent
ATS users (CFU)
Group 4: formerly
frequent, non-ATS
dependent users (FFU)
Group 5: non-frequent
ATS users (currently and
formerly) (NFU)
Group 6:
exposed non-
ATS users (ENU)
SDS positive (last 12
months)
SDS positive (any time
except last 12 months)
SDS negative lifetime SDS negative lifetime SDS negative lifetime SDS not
applicable
≥ 10 ATS
consumption days
within past 12
months
≥ 10 ATS consumption
days within a year except
past 12 months
≥ 10 ATS consumption
days within past 12
months
≥ 10 ATS consumption
days within a year except
past 12 months
< 10 ATS consumption
days within any given 12
months
Exposed to ATS
without ATS
consumption
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contact with drug treatment services (39.4%), in
particular those from group 1 (currently dependent)
and group 2 (formerly dependent). SDS screening
scores confirmed that participants in group 1 (cur-
rently dependent) and group 2 (formerly dependent)
were severely dependent, with mean SDS scores of
7.2 and 7.3, respectively [30]. Overall, 33.9% of the
sample had ever used ATS (almost) daily, 43.7% of
the ATS users consumed (almost) daily or at least
weekly amphetamines within the given time periods,
but with huge differences among the groups. Daily
or weekly amphetamine use was highest in group 1
(currently dependent) at 80.9%, and lowest in group
5 (non-frequent) at 22.4%. In groups 1 (currently
dependent) and 2 (formerly dependent), 21.3% and
30.4% took methamphetamines frequently, but no
use was reported from group 5 (non-frequent). Daily
or weekly MDMA use was evidence in around 30%
of the ATS users, but again, group 5 (non-frequent)
had the lowest rate of frequent MDMA use.
Across all ATS user groups, more than 90%
reported lifetime cannabis use, even in group 6 (non-
ATS users, at almost 80%). More than half of all re-
spondents reported lifetime cocaine use, with the
Table 2 Sample size by country and study group
Group 1:
currently ATS
dependent
(CDU)
Group 2: formerly
ATS dependent
users (FDU)
Group 3: currently
frequent, non-
dependent ATS
users (CFU)
Group 4: formerly
frequent, non-ATS
dependent users (FFU)
Group 5: non-frequent
ATS users (currently and
formerly) (NFU)
Group 6:
exposed non-
ATS users (ENU)
Total
Germany 9 17 12 6 9 7 60
United Kingdom 12 14 9 11 11 11 68
Poland 10 10 12 5 15 9 61
The Netherlands 10 10 10 10 10 10 60
Czech Republic 6 5 5 5 4 5 30
Total 47 56 48 37 49 42 279
Table 3 Characteristics of the interviewees by study group
Group 1:
currently ATS
dependent
(CDU)
Group 2:
formerly ATS
dependent
users (FDU)
Group 3: currently
frequent, non-
dependent ATS
users (CFU)
Group 4: formerly
frequent, non-ATS
dependent users
(FFU)
Group 5: non-frequent
ATS users (currently
and formerly) (NFU)
Group 6:
exposed non-
ATS users
(ENU)
Total
N 47 56 48 37 49 42 279
Female 46.8% 44.6% 25.0% 45.9% 40.8% 45.2% 41.2%
Mean age (SD) 32.2 (7.7) 33.6 (8.6) 29.3 (6.8) 32.6 (9.5) 31.0 (7.6) 28.8 (6.8) 31.3
(8.0)
Mean age of onset/exposure
ATS use (SD)
16.6 (2.2) 17.6 (4.7) 18.6 (4.0) 17.0 (4.3) 18.8 (3.8) 17.6 (3.4) 17.7
(3.9)
Mean duration of ATS use/
exposition in years (SD)
15.5 (8.0) 12.5 (6.8) 10.7 (5.3) 9.9 (6.8) 8.5 (6.5) 11.2 (6.1) 11.5
(6.9)
Ever contact with drug service 68.1% 78.6% 25.0% 29.7% 22.4% 0.0% 39.4%
SDS ATS score (SD) 7.2 (2.8) 7.3 (3.4) 1.9 (1.6) 2.2 (1.8) 0.3 (1.2) 0.0 (0.0) 3.3
(3.8)
Daily ATS use (almost) 74.5% 70.9% 20.8% 22.2% 4.1% 0.0% 33.9%
Daily/weekly amphetamine use 80.9% 71.4% 45.8% 29.7% 22.4% 0.0% 43.7%
Daily/weekly methamphetamine
use
21.3% 30.4% 6.3% 10.8% 0.0% 0.0% 12.2%
Daily/weekly MDMA use 44.7% 50.0% 37.5% 35.1% 10.2% 0.0% 30.5%
Ever used cannabis 91.5% 96.4% 91.7% 94.6% 91.8% 78.6% 91.0%
Ever used cocaine 66.0% 62.5% 60.4% 83.8% 51.0% 4.8% 54.8%
Ever daily alcohol use 48.9% 51.8% 27.1% 40.5% 42.9% 28.6% 40.5%
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prevalence highest in group 4 (former frequent) and
lowest in group 6 (non-ATS users) at 83.8% versus
4.8%. With regard to alcohol consumption, around
40% of the sample report having ever drunk alcohol
on a daily basis, rising to around half of respondents
from the two ATS-dependent groups.
Analysis
A total of 3547 life events were documented in the
life course charts for the 279 interviewees, each of
which referred to the respective time period when the
event occurred. The life events were extracted from
the life course charts, with multiple same responses
aggregated to a single entry and disconnected from
any interviewee information. In order to analyse the
life events, experienced researchers based in the re-
spective national research institutions normatively
rated each event either as positive, negative or neu-
tral, where neutral means that the life event could
not be rated as positive nor negative because accord-
ing to the normative judgement of the national ex-
perts it was neither positive nor negative. As such,
the meaning attributed to each event could reflect the
cultural importance of certain life events in relation
to each national field site, for example, marriage
(positive in Poland), living with a partner (neutral in
the UK, positive in other countries) and university
degree (positive in Germany, neutral in the UK).
Table 4 shows examples for the ratings in the defined
11 life domains. None of the interviewees ascribed
any positive life event in the categories illness or
criminal justice system.
For each person, we calculated the cumulated sum
of negative, positive and neutral life events at differ-
ent points in time for all life domains together, as
well as the sum for negative life events for every
single life domain. An empty cell in the life course
chart for life events was counted for the sum scores
as zero. The sums of life events serve in our models
as the dependent variable. For the analysis of the life
events in the entire life course, we applied an age-
adjusted factorial analysis of covariance ANCOVA,
with the independent variables study group and
country. For the analysis of life events while using
ATS, we calculated a duration-adjusted ANCOVA in
which for group 6 (non-ATS users) we determined
the duration from age at first ATS exposition to the
current age. For comparing the six groups (independ-
ent variable), we computed univariate analysis of
analysis of variance (ANOVA) and ANCOVA in SPSS
[31] and chose partial ETA squared as an indicator of
the effect size, where 0.01 is considered as small, 0.06
as medium and 0.14 as large effect [32]. A p value of
< 0.05 was employed to state statistical significance.
Table 4 Examples for ratings of the life events according to the life domain
Life
domain
Positive Negative Neutral
Parents/
family
Caring, supportive parents Divorce of parents, parental alcohol
dependence, domestic violence
Being adopted, in general good family
relationships
School Completed post-compulsory, graduation,
certification
Excluded from school, bullying, not
completed school
Completed school
Education/
work
Started University, regular/proper work Unemployment, stressful job, dealing
drugs
Temporary employment, full-time
employment
Friends Good social network, drug-free friends,
having best friends
No friends, social isolation, drug using/
dealing friends
Partying or clubbing with friends
Romantic
partner
New romantic relationship, marriage,
stable partnership
Drug using partner, divorce, separation,
domestic violence
Being single, divorce, multiple sex partners
Living Having own flat, with own family/
children
Homeless, kicked-out of home, assisted
living
Alone, with parents, with boyfriend, in hostel
Illness Mental health problems, self-harm,
physical injuries
Diagnosed with attention deficit hyperactivity
disorder, physical recovery in hospital
Criminal
justice
system
Imprisonment, conviction, arrests Drug-related crime, occasional/minor
offenses
Treatment Detoxification, outpatient drug
treatment, psychotherapy, psychiatry
In hospital, in psychiatry Detoxification, psychiatry, rehabilitation
Religion/
spirituality
Yoga, meditation Strong aversion to faith and church Catholic upbringing, atheist
Leisure Travelling, playing music, sport Boredom, social isolation, drug use, always
staying at home
Clubbing, festivals, raves
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These data analysis were largely explorative, but the
following hypotheses were guiding some parts of the
analysis:
1. Dependent ATS users will show more negative life
events in total
2. Dependent ATS users will show more negative life
events before the onset of ATS use
3. Dependent ATS users will show more negative life
events from the time period using ATS
Results
Overall, 1523 life events rated as neutral, 1005 life events
as positive and 1019 life events as negative.
We did not observe any statistically significant dif-
ferences between males and females in an age-
adjusted ANCOVA for the total positive life events
(male, 1.7 (SD = 2.2); female, 1.9 (SD = 2.2)), total
neutral life events (male, 2.5 (SD = 3.3); female, 3.0
(SD = 3.3)) and total negative life events (male, 1.6
(SD = 1.8); female, 2.0 (SD = 2.4)). Only the com-
bined sum of positive, neutral and negative life events
(male, 5.8 (SD = 4.6); female, 6.9 (SD = 5.3)) showed
statistically significant group differences (F(1,276) =
3.92, p = 0.049).
A two-way age-adjusted ANCOVA was conducted
to compare the main effects of the independent vari-
ables study group and country and the interaction ef-
fects between study group and country on the sum of
all four categories of documented life events. The
average sum of all documented life events did not dif-
fer significantly between the groups, ranging from
13.6 in group 2 (formerly dependent) to 11.4 in group
3 (currently frequent). No significant differences were
observed for the neutral life events, which ranged
from 6.7 in group 6 to 4.5 in group 3 (Table 5). The
average number of positive life events per person was
lowest for group 1 (currently dependent), with 2.1
documented positive life events in the entire life
course, and highest among group 3 (currently fre-
quent) and group 4 (formerly frequent) at 4.0. How-
ever, despite these group differences, the ANCOVA,
adjusted for age, failed to show statistical significance.
Both dependent ATS user groups (CDU and FDU) re-
ported considerably more negative life events than the
other four groups. The dependent users (CDU and FDU)
appeared on the upper end of cumulated negative life
events, whereas the frequent users and the non-frequent
users (CFU, FFU and NFU) were in the middle, and the
exposed non-ATS users (ENU) showed the lowest num-
ber. The age-adjusted ANCOVA showed a statistically sig-
nificant difference between groups (F(5,248) = 9.89, p =
0.000). The group effect was large (ηp
2 = 0.17).
The country effects were statistically significant for all
four scores of life events: positive life events (F(4,248) =
33.57, p = 0.000, ηp
2 = 0.35); neutral life events (F(4,248)
= 28.13, p = 0.000, ηp
2 = 0.31); negative life events ((F(4,
248) = 2.80, p = 0.026, ηp
2 = 0.04); all life events ((F(4,
248) = 9.78, p = 0.000, ηp
2 = 0.14).
The interaction effect between study group and coun-
try did not become significant for any of the four life
event scores: positive life events (F(20,248) = 1.58, p =
0.058, ηp
2 = 0.113), neutral life events (F(20,248) = 1.25,
p = 0.212, ηp
2 = 0.092), negative life events ((F(20,248) =
0.81, p = 0.697, ηp
2 = 0.062) and all life events ((F(20,
248) = 1.333, p = 0.159, ηp
2 = 0.097).
In order to investigate negative life events in more
depth, the group differences were analysed for each of
the life domains in respect of the cumulated sum of
negative life events. Highest mean sums for negative life
events are reported for the dependent user groups with
1.16 (formerly dependent) and 1.15 (currently
dependent) in the domain parents/family. For the do-
mains parents/family, friends, romantic partner and ill-
ness, we found that dependent ATS user groups showed
higher sums of negative life events over the entire life
course in comparison to the four other groups. The
ANCOVA, age-adjusted, demonstrates statistically
Table 5 In the entire life course: mean number and standard deviation (SD) of life events by groups, two-way ANCOVA (group and
country), age-adjusted
Group 1:
currently ATS
dependent
(CDU)
Group 2:
formerly ATS
dependent
users (FDU)
Group 3: currently
frequent, non-
dependent ATS
users (CFU)
Group 4: formerly
frequent, non-ATS
dependent users
(FFU)
Group 5: non-frequent
ATS users (currently and
formerly) (NFU)
Group 6:
exposed
non-ATS
users (ENU)
Total F(5,
248)
p ηp
2
Positive life
events (SD)
2.1 (2.4) 3.9 (3.7) 4.0 (3.7) 4.0 (4.1) 3.7 (5.3) 3.9 (4.4) 3.6
(4.0)
2.19 0.056 0.04
Neutral life
events (SD)
5.4 (4.8) 4.5 (4.0) 4.8 (5.1) 6.3 (5.7) 5.6 (5.6) 6.7 (6.0) 5.5
(5.2)
0.97 0.436 0.19
Negative life
events (SD)
5.3 (2.9) 5.2 (3.2) 2.7 (2.9) 3.3 (2.5) 2.9 (2.1) 2.1 (2.1) 3.7
(2.9)
9.89 0.000 0.17
All life events
(SD)
12.8 (5.9) 13.6 (6.1) 11.4 (7.2) 13.6 (9.7) 12.2 (9.2) 12.7 (7.5) 12.7
(7.6)
0.22 0.955 0.04
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significant group differences with low to medium effect
sizes (Table 6). Group differences for other life domains,
such as criminal justice system and leisure, fell just short
of reaching statistical significance.
The sum of all life events occurring until the first ATS
use or exposition did not show group differences. How-
ever, there were significant differences between groups
for the number of positive, neutral and negative life
events (Table 7). Neutral life events were higher in the
exposed non-ATS user group (ENU) and fewest in the
currently dependent ATS user group (CDU). The
ANOVA demonstrated statistically significant differ-
ences between both groups (F(5,273) = 3.29, p = 0.007).
The positive life events revealed a similar trend for the
groups (F(5,273) = 2.27, p = 0.048). The combined sum
of negative life events occurring before first use or ex-
position to ATS were highest for the two dependent
groups, lower for the non-dependent user groups, and
lowest of all for the non-users (F(5,273) = 2.37, p =
0.039). However, the group size effects on the observed
differences in positive, neutral and negative life events
are small.
The duration of ATS use for the five user groups and
the exposure to ATS for the non-ATS user group (ENU)
showed group differences (Table 3). Therefore, we
applied an ANCOVA adjusted by the duration of ATS
use to test for group differences with regard to life
events in the time between the onset and desistance of
ATS use (Table 8)
The reported sum of all life events while using ATS
differs significantly between groups, ranging from 4.2
(SD = 4.6) in group 5 (non-frequent) to 8.8 (SD =
5.1) in group 1 (currently dependent). The number of
neutral life events also differed significantly. The posi-
tive life events showed no group effects. The negative
life events while using ATS were comparably low in
the four non-dependent groups, but up to 3.7 times
higher for the two dependent groups (CDU and
FDU). The lowest number of negative life events were
found among group 5 (NFU) with 0.9 while using
ATS, and the highest in group 1 (CDU) with 3.3. The
duration adjusted ANCOVA showed statistically sig-
nificant differences between the groups (F(5,272) =
13.16, p = 0.000). The partial ETA squared demon-
strated a large size effect (ηp
2 = 0.20).
Discussion
Findings from our analysis of drug use and life event
data from 279 ATS user and non-users across Europe
demonstrate clear differences amongst our six pre-
Table 6 In the entire life course by life domains: mean number and standard deviation of negative life events by groups and life
domain, ANCOVA, age-adjusted
Life
domain
Group 1:
currently ATS
dependent
(CDU)
Group 2:
formerly ATS-
dependent
users (FDU)
Group 3: currently
frequent, non-
dependent ATS
users (CFU)
Group 4: formerly
frequent, non-ATS-
dependent users
(FFU)
Group 5: non-
frequent ATS users
(currently and
formerly) (NFU)
Group 6: exposed
non-ATS users
(ENU)
Total F
(5, 272)
p ηp2
Parents/
family (SD)
1.15 (1.10) 1.16 (1.11) 0.71 (1.17) 0.81 (0.91) 0.55 (0.84) 0.76 (1.05) 0.87
(1.06)
2.84 0.016 0.05
School 0.15 (0.36) 0.23 (0.43) 0.06 (0.24) 0.11 (0.39) 0.22 (0.55) 0.10 (0.30) 0.15
(0.40)
1.83 0.106 0.03
Education/
work
0.23 (0.48) 0.32 (0.47) 0.10 (0.31) 0.19 (0.46) 0.22 (0.47) 0.10 (0.30) 0.20
(0.43)
1.38 0.233 0.03
Friends 0.83 (1.32) 0.55 (0.83) 0.29 (0.54) 0.32 (0.58) 0.39 (0.70) 0.24 (0.58) 0.45
(0.83)
3.12 0.009 0.05
Romantic
partner
0.36 (0.79) 0.39 (0.68) 0.19 (0.49) 0.11 (0.31) 0.06 (0.24) 0.07 (0.26) 0.21
(0.54)
4.17 0.001 0.07
Living 0.53 (0.80) 0.48 (0.69) 0.17 (0.43) 0.38 (0.76) 0.45 (0.79) 0.29 (0.92) 0.39
(0.74)
1.20 0.309 0.02
Illness 1.02 (1.15) 1.14 (1.31) 0.73 (1.27) 0.68 (0.88) 0.51 (0.87) 0.45 (0.74) 0.77
(1.10)
3.11 0.010 0.05
Criminal
justice
system
0.77 (1.11) 0.64 (1.02) 0.27 (0.96) 0.54 (1.14) 0.35 (0.78) 0.12 (0.33) 0.46
(0.95)
2.22 0.053 0.04
Treatment 0.04 (0.20) 0.02 (0.13) 0.02 (0.14) 0.08 (0.28) 0.02 (0.14) 0.00 (0.00) 0.03
(0.17)
1.08 0.373 0.02
Religion/
spirituality
0.04 (0.29) 0.00 (0.00) 0.04 (0.20) 0.03 (0.16) 0.04 (0.20) 0.02 (0.15) 0.03
(0.19)
0.39 0.854 0.01
Leisure 0.15 (0.62) 0.23 (0.63) 0.08 (0.28) 0.08 (0.28) 0.04 (0.20) 0.00 (0.00) 0.10
(0.42
1.92 0.090 0.03
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defined user groups, both in terms of the types of
ATS used, and in relation to patterns of consumption
(Table 2). Intensive, daily ATS use was evident in
groups 1 and 2 (dependent—CDU and FDU) and in-
dicative of the overall severity of their drug “career”.
In contrast, this consumption pattern was consider-
ably less common in groups 3 and 4 (frequent—CFU
and FFU). The type of ATS consumed was also asso-
ciated with severe (or dependent) use trajectories.
Specifically, we found that methamphetamine use was
markedly more prevalent amongst current or former
dependent user (group 1 and 2 compared to groups
3, 4 and 5), involving periods of daily or at least
weekly consumption. We found similar patterns of
intensive use amongst groups 1 and 2 (dependent—
CDU and FDU) for other non-amphetamine sub-
stances, which again contrasted with that reported by
our other user groups.
Whilst few differences were seen in the total num-
ber of life events reported by different ATS user and
non-user groups, we found significant associations be-
tween the number and type of negative life events
and ATS consumption trajectories. Exposed non-users
and non-dependent ATS users, regardless of the fre-
quency of use, reported lower rates of adverse life
events than dependent users.
Dependent users, both current and former, reported
higher rates of negative life events before their first use
of ATS, and fewer positive or neutral experiences. Al-
though small, these differences were nevertheless statis-
tically significant and may suggest that dependent users
are more likely to have experienced difficulties during
childhood and adolescence.
Negative life events after the initiation of ATS use can
be partially interpreted as consequences of the substance
use patterns and our results point out that these numer-
ous consequences are exclusively limited to the
dependent or formerly dependent users of group 1 and
group 2. We do not find any significant differences be-
tween the other four groups.
At the same time, the negative life events experi-
enced by dependent ATS users appeared to derive
from a variety of life domains, making it challenging
to identify clear and causal pathways. Whilst existing
evidence implies that experiencing negative life events
results in sustained ATS consumption [6, 10, 20], our
study suggests holistic, tailored interventions and spe-
cialist treatment services are needed for this group, as
a single, simple intervention is unlikely to cover all
the life domains affected. A standardised short screen-
ing tool for life domains affected by negative life
events for dependent ATS user in contact with drug
Table 7 Until the first ATS use/exposure: mean number and standard deviation (SD) of life events, ANOVA
Group 1: currently
ATS dependent
(CDU)
Group 2: formerly
ATS dependent
users (FDU)
Group 3:
currently
frequent,
non-dependent
ATS users (CFU)
Group 4: formerly
frequent, non-ATS-
dependent users
(FFU)
Group 5: non-
frequent ATS
users (currently
and formerly)
(NFU)
Group 6:
exposed
non-ATS
users (ENU)
Total F(5,
273)
p ηp
2
Positive life
events (SD)
0.40 (0.88) 1.07 (1.74) 1.38 (1.61) 1.19 (2.42) 1.67 (3.15) 1.60 (2.12) 1.21
(2.11)
2.27 0.048 0.040
Neutral life
events (SD)
1.55 (1.53) 1.38 (1.67) 2.13 (2.77) 2.62 (2.88) 2.94 (3.72) 3.17 (3.75) 2.24
(2.87)
3.29 0.007 0.057
Negative life
events (SD)
1.96 (1.88) 2.05 (1.73) 1.42 (2.02) 1.65 (1.72) 1.33 (1.39) 1.07 (1.39) 1.60
(1.73)
2.37 0.039 0.042
All life
events (SD)
3.91 (3.05) 4.50 (3.26) 4.92 (4.12) 5.46 (5.65) 5.94 (6.27) 5.83 (4.96) 5.05
(4.65)
1.39 0.228 0.025
Table 8 Continued ATS use: mean number and standard deviation (SD) of life events by groups, ANCOVA, duration-adjusted
Group 1:
currently
ATS dependent
(CDU)
Group 2:
formerly
ATS-dependent
users (FDU)
Group 3:
currently
frequent,
non-dependent-
ATS users (CFU)
Group 4:
formerly
frequent,
non-ATS-
dependent
users (FFU)
Group 5:
non-frequent
ATS users
(currently
and formerly)
(NFU)
Group 6:
exposed
non-ATS
users (ENU)
Total F
(5, 272)
p ηp2
Positive life events (SD) 1.7 (2.0) 2.0 (2.2) 1.9 (1.9) 1.5 (1.6) 1.5 (2.5) 2.2 (2.8) 1.8 (2.2) 0.73 0.605 0.01
Neutral life events (SD) 3.8 (4.3) 2.5 (3.1) 2.2 (3.2) 2.5 (2.7) 1.8 (2.4) 3.5 (3.5) 2.7 (3.3) 2.98 0.012 0.05
Negative life
events (SD)
3.3 (2.5) 2.6 (2.7) 0.9 (1.0) 1.4 (1.6) 0.9 (1.2) 1.1 (1.3) 1.7 (2.1) 13.16 0.000 0.20
All life events (SD) 8.8 (5.1) 7.1 (5.4) 5.0 (3.9) 5.4 (4.2) 4.2 (4.6) 6.8 (4.7) 6.2 (4.9) 5.75 0.000 0.10
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services could serve as a guiding action for further
support.
For frequent and non-frequent ATS users negative life
events from the period of ATS use do not become obvi-
ous in our analysed data. Besides preventing a pathway
into ATS dependency, the aim of an intervention should
be to reduce the harm from the illicit drug itself.
Evidence suggests this can be achieved by offering qual-
ity and quantity control through drug testing which is
well accepted by the users and offers the opportunity for
interventions to prevent developing a substance use
dependency [33].
Overall, our findings show that formerly or current
ATS dependent users are more likely to have experi-
enced higher numbers of negative life events compared
to other user groups. However, at present, there is no
standardised instrument available to support accurate
measurement of negative life events. The development
and implementation of such an instrument would be
helpful in counselling and treatment settings to provide
adequate responses to clients' needs.
Strengths and limitations
The whole spectrum of ATS careers including ongoing
and former use, and ranging from dependent use to
non-dependent use; from frequent to non-frequent use,
as well as non-use, and experienceor no experience with
drug treatment, are represented in the sample and the
six groups.
In order to reveal more accurately the context of
“change” for ATS trajectories, we established the inclusion
criterion “ATS abstinence in the last 12months” for group
2 (FDU—formerly ATS-dependent users) and group 4
(FFU—formerly frequent, non-ATS-dependent users).
The use of a calendar technique such as timelines [34]
for the combination of life events and time points is
novel and understudied in the field of substance use in
general [26, 35, 36] has yet not been used for examining
stimulant use and might tackle partially the individual
recall bias of life events.
ATS covers a variety of different substances and the
often-observed use of more than one type of ATS in life
by the respondents has not been explored in detail in
this study as well as the effect of a single ATS. We also
have significantly more methamphetamine users in the
dependent user groups (CDU and FDU); therefore, we
cannot rule out that some results are influenced by the
specific experiences of this user group. The same can be
said in relation to other poly-substance use and non-
amphetamine substances consumed by the respondents.
Although further results from the ATTUNE project
should disclose such interactions.
The age periods in the life course charts utilised were
relatively large. We also only recorded one life event per
domain therefore multiple occurrences of life events
could have occurred and could have gone unrecorded.
This could have resulted in both the underreporting of
the sum of life events per domain but also in total. Fur-
ther, our focus on negative life events might have con-
cealed consideration of positive life events that serve as
protective factors.
Whilst our sample was relatively substantial (n = 279),
we cannot fully adjust for differences such as country,
ATS consumed or other, may be important, participant
characteristics due to small numbers per specific group/
variable.
The life chart data analysed was collected during semi-
structured qualitative interviews and quasi-isolated from
the rich in-depth interview data. The sample size, the
systematic and the number of recorded life events in the
life charts gave us the opportunity to employ standar-
dised methods to test for statistical inferences, although
such a method is rather untypical for in-depth qualita-
tive interview data.
Conclusions
By purposeful sampling of five ATS user groups and one
ATS-exposed non-user group, we were able to study the
association between ATS pathways and life events in the
entire life course. The data was systematically collected
using life course charts to capture key life events and
substance use histories during in-depth qualitative inter-
views. The applied method is novel for the examination
of ATS trajectories.
Dependent ATS users experienced more negative life
events for the entire life course after age adjustment.
Whilst, some of the group differences found could be at-
tributed to the life course prior to ATS use, most negative
life events resulted from periods of ATS usage. A detailed
analysis of the specific life domains reveals that the social
environment was most likely to be that affected by the
negative life events. No difference between the groups of
non-dependent, frequent and non-frequent ATS users
and exposed non-ATS users were found.
For non-dependent, frequent and non-frequent ATS
users, negative life events from the period of ATS use do
not become obvious in our analysed data. Besides pre-
venting a pathway into ATS dependency, the aim of an
intervention should be to reduce the harm by for ex-
ample drug testing which offers also the opportunity for
interventions to prevent developing a substance use
dependency.
For the group of dependent ATS users, our study
suggests holistic, tailored interventions and specialist
treatment services are needed, as a single, simple
intervention is unlikely to cover all the life domains
affected.
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